BARCELONA, Spain and DÜSSELDORF, Germany, July 24, 2026 -- Minoryx Therapeutics and Neuraxpharm Group, announce that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has...
LipoScience Sets IPO Term
News | 01. 10. 2013
NEW YORK--LipoScience Inc. set terms for its initial public offering Thursday, with the diagnostics company looking to raise as much as $75 million and become the first health-care company to go public this year.
The company said in a filing with the Securities and Exchange Commission that it expects to fetch between $13 and $15 each for its five million shares.
The company develops medical diagnostic tests and analytics tools. Its key product measures low-density lipoprotein, or LDL, particles in blood. The particles can provide clues about heart disease.
